Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA May Revisit Accelerated Approval For Oncology Products

Executive Summary

FDA's oncology division is interested in revisiting the accelerated approval regulations as they apply to cancer treatments
Advertisement

Related Content

“Optimal” Dose Finding Could Result In More Late-Stage Drug Success
“Optimal” Dose Finding Could Result In More Late-Stage Drug Success
Millennium Velcade Multiple Myeloma Launch Expected In Late 2003
Millennium Velcade Multiple Myeloma Launch Expected In Late 2003
Accelerated Approval Standards Will Be Advisory Committee Topic In March
Accelerated Approval Standards Will Be Advisory Committee Topic In March
HIV Trials Should Focus On Pre-Treated Patients, FDA Guidance Says
Iressa Cross-Over Study Could Show Clinical Benefit, AZ Says; ODAC Is Wary
Sanofi Eloxatin First-Line Colorectal Cancer Data Will Be Submitted By 2003
Sanofi Eloxatin First-Line Colorectal Cancer Data Will Be Submitted By 2003
Advertisement
UsernamePublicRestriction

Register

PS040649

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel